SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Squamous Non-Small Cell Lung Cancer.

Apr 19, 2024 - 00:00
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Squamous Non-Small Cell Lung Cancer.

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow